Company: CMND
Filing Date: 2025-11-17
Form Type: 424B5
Source: 0001213900-25-111233
Chunk: 29

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-17
Form: 424B5
Chunk 29
---
uer on Form 6-K in connection with this offering and incorporated by reference
into the registration statement of which this prospectus forms a part. Prospective investors should carefully review the terms and provisions
of the form of warrant for a complete description of the terms and conditions of the pre-funded warrants.

The term “pre-funded”
refers to the fact that the purchase price of our Common Shares in this offering includes almost the entire exercise price that will be
paid under the pre-funded warrants, except for a nominal remaining exercise price of $0.0001. The purpose of the pre-funded warrants is
to enable investors that may have restrictions on their ability to beneficially own more than 4.99% (or, upon election of the holder,
9.99%) of our outstanding Common Shares following the consummation of this offering the opportunity to make an investment in the Company
without triggering their ownership restrictions, by receiving pre-funded warrants in lieu of our Common Shares which would result in such
ownership of more than 4.99% (or 9.99%), and receive the ability to exercise their option to purchase the shares underlying the pre-funded
warrants at such nominal price at a later date.

Exercise of Pre-Funded Warrants.Each
pre-funded warrants is exercisable for one Common Share, with an exercise price equal to $0.0001 per Common Share, at any time that the
pre-funded warrants is outstanding. There is no expiration date for the pre-funded warrants. The holder of a pre-funded warrants will
not be deemed a holder of our underlying Common Shares until the pre-funded warrants is exercised.

Subject to limited exceptions,
a holder of pre-funded warrants will not have the right to exercise any portion of its pre-funded warrants if the holder (together with
such holder’s affiliates, and any persons acting as a group together with such holder or any of such holder’s affiliates)
would beneficially own a number of Common Shares in excess of 4.99% (or, at the election of the purchaser prior to the date of issuance,
9.99%) of the Common Shares then outstanding after giving effect to such exercise.

The exercise price and the
number of Common Shares issuable upon exercise of the pre-funded warrants is subject to appropriate adjustment in the event of recapitalization
events, stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting our Common Shares.
The pre-funded warrant holders must pay the exercise price in cash upon exercise of the